Seattle Genetics Slaps Big Price on New Cancer Drug
Seattle Genetics (SGEN) is the latest company to test the market for high-priced new drugs announcing plans Monday to charge six figures for the just-approved treatment Adcetris for two types of blood cancer.Seattle Genetics said the drug will cost between $94 500 and $121 500 per patient depending on the number of doses. The price could run even higher because it’s unknown how many doses each patient will require. (The company estimated the price based on seven to nine infusions per patient.) The pricing announcement follows Friday’s news that Adcetris received a fast US Food and Drug Administration approval ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here